eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

Sorafenib may reduce endothelial nitric oxide synthase (eNOS) activity by inhibiting vascular endothelial growth factor receptors (VEGF-R), leading to a decrease in nitric oxide production. In the Italian multicenter ePHAS (eNOS polymorphisms in HCC and sorafenib) study, we analyzed the role of eNOS...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Gardini, Andrea Casadei, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Valgiusti, Martina, Facchetti, Floriana, Corte, Cristina della, Neri, Luca Maria, Tamberi, Stefano, Cascinu, Stefano, Scartozzi, Mario, Amadori, Dino, Nanni, Oriana, Tenti, Elena, Ulivi, Paola, Frassineti, Giovanni Luca
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2016
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5053704/
https://ncbi.nlm.nih.gov/pubmed/27058899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8569
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items